What Exactly are Point-of-Care Diagnostics?
Point-of-care diagnostics refers to a medical diagnostic testing process that takes place at or near the site of patient care, rather than in a centralized laboratory or hospital setting. These tests are designed to deliver rapid and reliable results that help healthcare providers make quick, informed decisions regarding patient diagnosis and treatment. The goal is to enable immediate decision-making without the need for a patient to wait for results or travel to another location for testing.
Point-of-care diagnostics is a rapidly advancing field that enables healthcare professionals and patients to perform diagnostic tests at or near the site of care. With growing adoption and innovations, point-of-care diagnostics is transforming healthcare delivery by making diagnostics faster, more accessible, and more efficient.
The point-of-care diagnostics market is experiencing significant growth due to increasing demand for accessible, efficient, and cost-effective diagnostic solutions. The market's expansion is driven by technological advancements, an aging population, rising incidences of chronic diseases, and the growing adoption of home-based testing.
With rapid innovations in mobile health integration, artificial intelligence (AI), and digital diagnostics, the market is evolving to meet the needs of healthcare providers and patients for faster, more reliable diagnostics at the point of care.
What is the market for point-of-care diagnostics?
The global point-of-care diagnostics market is poised for substantial growth from 2022 to 2033. In 2023, the market was valued at approximately US$ 14,343.73 million, with a rise to US$ 15,463.98 million in 2024 and is expected to reach US$ 32,629.03 million in 2033, exhibiting a CAGR of 8.7% during the forecast period (2025-2033).
Which are the top companies in the point-of-care diagnostics market?
Competitive overview of the top 4 companies:
Abbott:
- Abbott is one of the leading players in the global point-of-care (PoC) diagnostics market, providing a wide range of rapid, portable, and easy-to-use diagnostic solutions.
- Abbott remains a major contributor to the PoC diagnostics industry, driven by its broad product portfolio, continuous innovation, and strong market presence.
- Abbott is the leader in the global point-of-care diagnostics market, holding the highest share of 23.18% in 2024.
- Point-of-care diagnostics products offered by Abbott include the i-STAT CHEM8+ Cartridge, CHOLESTECH LDX ANALYZER, Afinion 2, Bioline Dengue Duo (Dengue NS1 Ag + IgG/IgM), i-STAT 1, ID NOW, AFINION CRP, and ID NOW RSV, among others.
F. Hoffmann-La Roche Ltd:
- Roche is a leading provider of in-vitro diagnostics and a global supplier of transformative innovative solutions across major diseases such as cancer, viral infections, central nervous system disorders, and inflammatory diseases.
- Roche has established itself as a leader in the PoC diagnostics sector by providing innovative solutions that enable quick and accurate patient testing.
- F. Hoffmann-La Roche Ltd holds the second highest share in the global point of care diagnostics in the healthcare market, holding 15.93% of the total market share.
- Point-of-care diagnostics products offered by F. Hoffmann-La Roche Ltd include the Cobas b 221 System, Cobas b 101 System, 9180 Electrolyte Analyzer, Cobas Pulse System, Cobas Liat System, Urisys 1100 Analyzer, Multiplate Analyzer, CoaguChek XS Pro System, CoaguChek XS Plus system, and CoaguChek INRange system, among other products
Danaher Corporation:
- Danaher Corporation is a major player in the global point-of-care (PoC) diagnostics market, providing innovative diagnostic solutions through its subsidiaries like HemoCue, Cepheid, and Beckman Coulter.
- Danaher's commitment to innovation ensures that its products meet the evolving needs of healthcare professionals.
- The company emphasizes research and development to introduce new technologies that improve diagnostic accuracy and accessibility.
- The company leverages cutting-edge PoC technologies, including PCR-based molecular diagnostics and microarray technologies, to improve diagnostic accuracy and accessibility in various healthcare settings.
- The company holds 11.23% of the global market share in point-of-care diagnostics.
- The point-of-care diagnostics products offered by HEMOCUE, the subsidiary of Danaher Corporation, include HemoCue Hb 201+ System, HemoCue Hb 301 System, HemoCue Plasma/Low Hb System, HemoCue WBC DIFF System, HemoCue WBC System, HemoCue HbA1c 501 System, and HemoCue Glucose 201+ System, among others.
Siemens Healthineers AG:
- Siemens Healthineers is a MedTech business with almost 125 years of expertise in the industry.
- Its portfolio, which includes image-guided therapy, revolutionary cancer care, and in vitro and in vivo diagnostics, is essential for medical decisions and treatment approaches.
- Siemens Healthineers is a key player in the global point-of-care (PoC) diagnostics market, offering a diverse portfolio of testing solutions that enhance rapid diagnostics across multiple healthcare settings.
- The company provides advanced PoC diagnostic solutions for infectious diseases, cardiometabolic conditions, and coagulation testing.
- Siemens Healthineers remains competitive by integrating AI-powered analytics and automation into PoC diagnostics, ensuring quick and precise results.
- Siemens Healthineers holds 10.28% of the total point-of-care diagnostics market share in 2024.
- Point-of-care diagnostics products offered by Siemens Healthineers AG include RAPIDPoint 500e Blood Gas System, Epoc Blood Analysis System with epoc NXS Host, Epoc Blood Analysis System, DCA Vantage Analyzer, Stratus CS Acute Care Troponin Analyzer, and CLINITEK Status+ Analyzer, among other products
Key developments by the top companies:-
- In February 2024, HemoCue partnered with Novo Nordisk to enhance point-of-care diagnostic testing for children with type 1 diabetes in low- and middle-income countries. This collaboration aims to improve access to essential diagnostic tools and care for children living with type 1 diabetes in these regions.
- In August 2024, HemoCue unveiled its revitalized brand. This rebranding represents a significant step in the company’s ongoing evolution, underscoring its dedication to addressing the evolving needs of the point-of-care diagnostics sector in a rapidly changing healthcare environment.
CONCLUSION:
The point-of-care diagnostics market is highly competitive, with leading players like Abbott Laboratories, Roche Diagnostics, and Siemens Healthineers driving innovation and expanding their product offerings. As these key market players continue to invest in research and development, the market is poised for significant growth, ultimately improving patient care and healthcare accessibility worldwide.
Point-of-care diagnostics are revolutionizing healthcare by enabling quicker, more accessible, and personalized testing. As technology continues to advance, these tools have the potential to further enhance patient outcomes and streamline healthcare delivery globally.
